聯(lián)系我們時請說明是91化工儀器網(wǎng)上看到的信息，謝謝!

產(chǎn)品簡介 品牌 MedChemExpress (MCE) 貨號 HY-18690 規(guī)格 10 mM * 1 mL；5 mg；10 mg 供貨周期 現(xiàn)貨 應(yīng)用領(lǐng)域 生物產(chǎn)業(yè)     Enasidenib是可口服，可逆，選擇性的 IDH2 突變酶抑制劑，抑制IDH2R140Q 和 IDH2R172K 的 IC50 分別為100 和 400 nM。
詳細(xì)介紹 Enasidenib

產(chǎn)品活性：Enasidenib是可口服，可逆，選擇性的 IDH2 突變酶抑制劑，抑制IDH2R140Q 和 IDH2R172K 的 IC50 分別為100 和 400 nM。

研究領(lǐng)域：metabolic Enzyme/Protease

作用靶點：Isocitrate Dehydrogenase (IDH)

In Vitro: Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2wks.

In Vivo: Treatment with Enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10mg/kg or 100mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production.

相關(guān)產(chǎn)品：FDA-Approved Drug Library Plus | Drug Repurposing Compound Library | FDA-Approved Drug Library Mini | FDA-Approved Drug Library | Anti-Cancer Compound Library | metabolism/Protease Compound Library | Drug Repurposing Compound Library Plus | Bioactive Compound Library Plus | Ivosidenib | AGI-5198 | Vorasidenib | AGI-6780 | GSK864 | IDH-305 | BAY-1436032 | Enasidenib mesylate | Mutant IDH1 inhibitor | Mutant IDH1-IN-1 | Mutant IDH1-IN-2 | IDH1 Inhibitor 1 | Mutant IDH1-IN-4 | Olutasidenib

以上信息由企業(yè)自行提供，信息內(nèi)容的真實性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé)，91化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示：為規(guī)避購買風(fēng)險，建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。 搜本商鋪 或 搜全站

MedChemExpress LLC - 主營產(chǎn)品： 西羅莫司 Rapamycin,瑞沙托維 TAK-242,奧拉帕尼 Olaparib

地址：上海市浦東新區(qū)張衡路1999弄3號樓      聯(lián)系電話：86-021-58955995      手機(jī)：18019480960     傳真：86-021-53700325
91化工儀器網(wǎng) 設(shè)計制作，未經(jīng)允許翻錄必究 .      Copyright(C) http://www.chem17.com,      All rights reserved. 以上信息由企業(yè)自行提供，信息內(nèi)容的真實性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé)，91化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示：為規(guī)避購買風(fēng)險，建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。
會員登錄